
MiMedx Group MDXG
$ 3.74
0.81%
Quarterly report 2026-Q1
added 04-29-2026
MiMedx Group Gross Profit 2011-2026 | MDXG
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit MiMedx Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 346 M | 289 M | 267 M | 220 M | 202 M | 209 M | 256 M | 323 M | 286 M | 192 M | 167 M | 106 M | 49.9 M | 21.9 M | 4.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 346 M | 4.6 M | 196 M |
Quarterly Gross Profit MiMedx Group
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.6 M | - | 79.9 M | 71.6 M | - | 68.7 M | 72.4 M | 71.7 M | - | 66.9 M | 67.7 M | 59.3 M | - | 55.5 M | 55.1 M | 49 M | - | 52.9 M | 55.4 M | 50.3 M | 57.7 M | 54 M | 45.4 M | 51.7 M | 63.7 M | 75.7 M | 57.7 M | 59.1 M | 82.2 M | 79.6 M | 86.1 M | 74.8 M | 78.5 M | 74.7 M | 72 M | 60.8 M | 60.8 M | 56.4 M | 49.9 M | 45.4 M | 46.8 M | 44 M | 40.6 M | 35.6 M | 36 M | 30.2 M | 22.8 M | 16.6 M | 14.9 M | 14 M | 11.3 M | 9.65 M | 8.82 M | 6.53 M | 3.77 M | 2.75 M | 1.72 M | 1.27 M | 1.08 M | 333 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 86.1 M | 333 K | 46.4 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | - | - | $ 162 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
275 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
22.7 M | $ 13.72 | 0.96 % | $ 388 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
532 M | $ 8.23 | -0.36 % | $ 1.24 B | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
18 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
IRIDEX Corporation
IRIX
|
19.2 M | $ 1.15 | 2.67 % | $ 19.5 M | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
5.52 M | $ 1.49 | 0.34 % | $ 32.9 M | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
LivaNova PLC
LIVN
|
940 M | $ 78.94 | 2.29 % | $ 4.31 B | ||
|
Cytosorbents Corporation
CTSO
|
26.5 M | $ 0.41 | -2.6 % | $ 25.5 M | ||
|
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.51 | -1.63 % | $ 61.4 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 18.53 | 0.22 % | $ 435 M | ||
|
Delcath Systems
DCTH
|
73.4 M | $ 11.54 | -1.28 % | $ 413 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
LENSAR
LNSR
|
14.1 M | $ 5.66 | -0.53 % | $ 67.7 M | ||
|
Orthofix Medical
OFIX
|
566 M | $ 9.97 | 0.96 % | $ 395 M | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
50 M | $ 36.96 | 1.57 % | $ 312 M | ||
|
Butterfly Network
BFLY
|
45.7 M | $ 5.47 | 6.53 % | $ 1.35 B | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
Myomo
MYO
|
26.9 M | $ 1.49 | 12.88 % | $ 62.4 M | ||
|
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
1.02 B | $ 81.52 | -1.22 % | $ 11 B | ||
|
Insulet Corporation
PODD
|
1.94 B | $ 156.0 | -2.26 % | $ 11 B | ||
|
Profound Medical Corp.
PROF
|
11.4 M | $ 6.9 | 1.17 % | $ 209 M | ||
|
CONMED Corporation
CNMD
|
750 M | $ 36.47 | -1.06 % | $ 1.13 B | ||
|
Inspire Medical Systems
INSP
|
779 M | $ 42.93 | 1.78 % | $ 1.26 B | ||
|
Integer Holdings Corporation
ITGR
|
500 M | $ 93.16 | -0.86 % | $ 3.24 B | ||
|
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
4.73 B | $ 86.56 | -1.1 % | $ 50.6 B | ||
|
Sintx Technologies
SINT
|
461 K | $ 2.11 | -0.24 % | $ 5.85 M |